Key result
2025 review highlights the top 10 papers refining clinical practice in thrombosis and antithrombotic therapy.
This review highlights the top 10 papers in thrombosis and antithrombotic therapy from 2025, summarizing key findings that refine clinical practice and explore new developments.
Several trials refine antithrombotic practice now; leaves open impact of novel developments and unmet needs in valve thrombosis.
Top 10 papers in 2025 on thrombosis and antithrombotic therapy. Several findings refine clinical practice (TARGET-FIRST, NEO-MINDSET, TACSI, AQUATIC, and COMBINE-AF); other investigations explore new developments (CELEBRATE, PRESTIGE-AF, ENBALV) and valve thrombosis management, or highlight unmet needs (ROPAC III). “<” indicates “significant reduction in rates of”; “>” indicates “significant increase in rates of”.
No takes yet. Share an insight, caveat, or question.
Andreotti et al. (2026) conducted a review in Thrombosis and antithrombotic therapy. Antithrombotic therapy was evaluated. The 2025 review highlights the top 10 papers in thrombosis and antithrombotic therapy, summarizing findings that refine clinical practice and explore new developments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: